Apples and oranges
- 1 March 2006
- journal article
- editorial
- Published by Wiley in BJU International
- Vol. 97 (3) , 435-438
- https://doi.org/10.1111/j.1464-410X.2006.06088.x
Abstract
No abstract availableThis publication has 31 references indexed in Scilit:
- Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancerBJU International, 2006
- Risks and Benefits of Hormonal Manipulation as Monotherapy or Adjuvant Treatment in Localised Prostate CancerEuropean Urology, 2005
- The androgen receptor pathway is by‐passed in prostate cancer cells generated after prolonged treatment with bicalutamideThe Prostate, 2005
- Structural basis for antagonism and resistance of bicalutamide in prostate cancerProceedings of the National Academy of Sciences, 2005
- Immediate Versus Deferred Hormonal Treatment for Patients With Prostate Cancer Who Are Not Suitable for Curative Local Treatment: Results of the Randomized Trial SAKK 08/88Journal of Clinical Oncology, 2004
- Molecular determinants of resistance to antiandrogen therapyNature Medicine, 2003
- Pretreatment Nomogram That Predicts 5-Year Probability of Metastasis Following Three-Dimensional Conformal Radiation Therapy for Localized Prostate CancerJournal of Clinical Oncology, 2003
- Phase III Trial of Long-Term Adjuvant Androgen Deprivation After Neoadjuvant Hormonal Cytoreduction and Radiotherapy in Locally Advanced Carcinoma of the Prostate: The Radiation Therapy Oncology Group Protocol 92–02Journal of Clinical Oncology, 2003
- Bicalutamide as Immediate Therapy Either Alone or as Adjuvant to Standard Care of Patients with Localized or Locally Advanced Prostate Cancer:Journal of Urology, 2002
- Immediate Hormonal Therapy Compared with Observation after Radical Prostatectomy and Pelvic Lymphadenectomy in Men with Node-Positive Prostate CancerNew England Journal of Medicine, 1999